These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29967424)

  • 1. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.
    Sjödahl G; Eriksson P; Lövgren K; Marzouka NA; Bernardo C; Nordentoft I; Dyrskjøt L; Liedberg F; Höglund M
    Mod Pathol; 2018 Dec; 31(12):1869-1881. PubMed ID: 29967424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal origin of lymph node metastases in bladder carcinoma.
    Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
    Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node.
    Malmström PU; Ren ZP; Sherif A; de la Torre M; Wester K; Thörn M
    J Urol; 2002 Nov; 168(5):2240-4. PubMed ID: 12394767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
    Warrick JI; Sjödahl G; Kaag M; Raman JD; Merrill S; Shuman L; Chen G; Walter V; DeGraff DJ
    Eur Urol; 2019 Jan; 75(1):18-22. PubMed ID: 30266310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
    Bontoux C; Rialland T; Cussenot O; Compérat E
    Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
    Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
    Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies.
    Han L; Gallan AJ; Steinberg GD; Sweis RF; Paner GP
    Hum Pathol; 2020 Dec; 106():54-61. PubMed ID: 32987034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
    Schallenberg S; Dragomir MP; Anders P; Ebner B; Volz Y; Eismann L; Rodler S; Casuscelli J; Buchner A; Klauschen F; Stief C; Horst D; Schulz GB
    Eur Urol Focus; 2023 Sep; 9(5):788-798. PubMed ID: 37076398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis.
    Jiang J; Ulbright TM; Younger C; Sanchez K; Bostwick DG; Koch MO; Eble JN; Cheng L
    Arch Pathol Lab Med; 2001 Jul; 125(7):921-3. PubMed ID: 11419977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
    Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
    Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathology of the luminal class of urothelial tumors.
    Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
    J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
    Sjödahl G
    Methods Mol Biol; 2018; 1655():53-64. PubMed ID: 28889377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.